Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993 May;67(5):1145-53.
doi: 10.1038/bjc.1993.211.

Phosphomonoester is associated with proliferation in human breast cancer: a 31P MRS study

Affiliations
Free PMC article

Phosphomonoester is associated with proliferation in human breast cancer: a 31P MRS study

R Kalra et al. Br J Cancer. 1993 May.
Free PMC article

Abstract

Phospholipid metabolism of human breast cancer was studied by 31P magnetic resonance spectroscopy (MRS). In vivo localised 31P MR spectra were obtained from the tumour alone using phase modulated rotating frame imaging. For 31 tumours, median (range) phosphomonoester (PME) to ATP ratio was 1.48 (0.57-3.78) and phosphodiester (PDE) to ATP ratio was 1.65 (0.44-3.89). DNA index and S phase fraction (SPF) were measured by flow cytometry of paraffin embedded tissue. Twelve (39%) tumours were diploid and 19 aneuploid. Median (range) SPF for 29 assessable tumours was 5.3% (0.6-28%), with significantly greater median SPF for aneuploid tumours (9.3%) than diploid (3.8%, P = 0.007). There was a significant association between PME/ATP and SPF (P = 0.03) due to a significant correlation for aneuploid tumours (P = 0.01). High resolution 31P MRS of extracts from 18 tumours (including seven studied in vivo) demonstrated that the PME peak consists predominantly of phosphoethanolamine (PE) with a smaller contribution from phosphocholine (PC) (median (range) PE/PC: 3.02 (1.13-5.09)). Changes in PME/ATP were observed for two tumours where tamoxifen stablized disease and may be consistent with the cytostatic effects of this drug.

PubMed Disclaimer

References

    1. Biochim Biophys Acta. 1984 Sep 14;805(1):104-16 - PubMed
    1. Lancet. 1984 Aug 18;2(8399):366-70 - PubMed
    1. Biochim Biophys Acta. 1985 Jan 28;838(1):175-8 - PubMed
    1. Lab Invest. 1985 Mar;52(3):287-91 - PubMed
    1. Lancet. 1985 Apr 13;1(8433):829-32 - PubMed

Publication types